Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06561425 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma
A Phase 1 study of Lymphomas Non-Hodgkin's B-Cell and Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma, sponsored by Galapagos.
- Active
- Registry status
- Phase 1
- Development phase
- 130
- Enrollment target
- 10
- Study locations
NCT06561425: Active Phase 1 study of Lymphomas Non-Hodgkin's B-Cell and Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma, sponsored by Galapagos.
NCT06561425 is a Phase 1 study of Lymphomas Non-Hodgkin's B-Cell and Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma that is active but no longer recruiting, run by Galapagos. The registered enrollment target is 130 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (117% higher). The trial reports 10 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06561425, a Phase 1 study of Lymphomas Non-Hodgkin's B-Cell and Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma, is active but no longer recruiting, sponsored by Galapagos.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 130 participants
- Enrollment target
- 10
- Study locations
Study Summary
This study is evaluating whether an experimental treatment called GLPG5101 helps to treat non-Hodgkin lymphoma (NHL) and if it is safe to use. This study will be carried out in 2 phases: * The first phase is to see which doses of GLPG5101 work best with the least number of side effects. * In the second phase, participants will receive the selected dose(s) based on the results in the first phase.
Conditions Studied
Interventions
- GENETIC GLPG5101
Study Locations (10)
Other
- Antwerp University Hospital - Edegem
- UZ Leuven - Leuven
- CHU De Liège - Liège
- Cliniques Universitaires Saint-Luc - Woluwe-Saint-Lambert
- Academisch Medisch Centrum - Amsterdam
- Leiden University Medical Center - Leiden
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) - Rotterdam
Massachusetts
- Tufts Medical Center - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2022-03-09 |
| Est. Completion | 2029-07-01 |
| Phase | Phase 1 |
What the registry record for NCT06561425 still lists
NCT06561425 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (117% higher).
The record links to 2 conditions, with Lymphomas Non-Hodgkin's B-Cell appearing as the primary indexed condition, and to 1 intervention - of which GLPG5101 is the first listed.
NCT06561425 lists 10 locations in 2 states (Other, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT06561425 about?
NCT06561425 is a clinical study titled "A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma". This study is evaluating whether an experimental treatment called GLPG5101 helps to treat non-Hodgkin lymphoma (NHL) and if it is safe to use. This study will be carried out in 2 phases: * The first phase is to see which doses of GLPG5101 work best with the least number of side effects. * In the s...
What is the current status of trial NCT06561425?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 130 participants. The study started on 2022-03-09. Estimated completion is 2029-07-01.
What conditions does trial NCT06561425 study?
This clinical trial studies the following conditions: Lymphomas Non-Hodgkin's B-Cell, Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT06561425?
The interventions under investigation include: GLPG5101 (GENETIC).
Who is sponsoring clinical trial NCT06561425?
This trial is sponsored by Galapagos, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06561425 being conducted?
This trial has 10 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphomas Non-Hodgkin's B-Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06561425's enrollment target sits among peer trials
130 439th of 2000 higher than 1,550 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492036 · 130 participants
Long-Term Follow-Up of Recipient of Gene Transfer Research
- NCT01631617 · 130 participants · Phase 2
Effects of Treatments on Atopic Dermatitis
- NCT02368041 · 130 participants
Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure
- NCT02604277 · 130 participants · NA
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI